STAGE III RENAL CELL CANCER AJCC V8

This study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the drugs for 12 weeks, then have surgery to remove the tumor. The …

This phase III trial compares the usual immunotherapy (nivolumab and ipilimumab followed by nivolumab alone) to the same treatment plus an additional drug called cabozantinib in 1,175 patients with advanced kidney cancer that has spread. The goal is to see if adding cabozantinib …

This early-phase trial tests whether adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) is safe and effective for people with advanced kidney cancer that has spread. About 31 participants will receive the combination to see if it improves gu…

This study tests a drug called adavosertib in adults with advanced solid tumors that lack a gene called SETD2. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them from getting worse.

This study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system attack cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes …